Lack of Adequate Study Plan Prompts EMA Review Of Cardiovascular Risk With Mysimba
Executive Summary
The European Medicines Agency is to recommend whether the marketing authorization for Currax’s weight management drug should be maintained, varied, suspended or revoked.
You may also be interested in...
Contrave OK'd in obesity; multiple trials required
Orexigen Therapeutics' and Takeda's anti-obesity drug Contrave (naltrexone SR/bupropion SR) was finally approved by the FDA on 10 September, but not without its many trials and tribulations along the way.
Europe’s Proposed Chemical Ban Could Hit Many Thousands Of Global Marketing Authorizations
Drug manufacturing in the EU would grind to a halt in under three years if a proposal to restrict per- and polyfluoroalkyl substances in the European Economic Area is implemented in its current form, says industry group EFPIA.
New EU Filings
Givinostat, Italfarmaco’s investigational treatment for Duchenne muscular dystrophy, is among the latest products that have been filed for review by the European Medicines Agency for potential EU marketing approval.